258 related articles for article (PubMed ID: 26095223)
1. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
Hattinger CM; Serra M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
[TBL] [Abstract][Full Text] [Related]
2. The pharmacogenomics of osteosarcoma.
Serra M; Hattinger CM
Pharmacogenomics J; 2017 Jan; 17(1):11-20. PubMed ID: 27241064
[TBL] [Abstract][Full Text] [Related]
3. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
5. Advances in emerging drugs for osteosarcoma.
Hattinger CM; Fanelli M; Tavanti E; Vella S; Ferrari S; Picci P; Serra M
Expert Opin Emerg Drugs; 2015 Sep; 20(3):495-514. PubMed ID: 26021401
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for high-grade osteosarcoma.
Hattinger CM; Pasello M; Ferrari S; Picci P; Serra M
Expert Opin Emerg Drugs; 2010 Dec; 15(4):615-34. PubMed ID: 20690888
[TBL] [Abstract][Full Text] [Related]
7. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
8. Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?
Kager L; Diakos C; Bielack S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1025-8. PubMed ID: 25882838
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics for individualized cancer chemotherapy.
Efferth T; Volm M
Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
[TBL] [Abstract][Full Text] [Related]
10. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics in cancer treatment.
Nagasubramanian R; Innocenti F; Ratain MJ
Annu Rev Med; 2003; 54():437-52. PubMed ID: 12525681
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.
Donnelly JG
Ther Drug Monit; 2004 Apr; 26(2):231-5. PubMed ID: 15228171
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenetics of anticancer drugs].
de Chaisemartin L; Loriot MA
Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
[TBL] [Abstract][Full Text] [Related]
14. Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.
Li S; Sun W; Wang H; Zuo D; Hua Y; Cai Z
Tumour Biol; 2015 Mar; 36(3):1329-38. PubMed ID: 25666750
[TBL] [Abstract][Full Text] [Related]
15. The safety of current pharmacotherapeutic strategies for osteosarcoma.
Spalato M; Italiano A
Expert Opin Drug Saf; 2021 Apr; 20(4):427-438. PubMed ID: 33478264
[No Abstract] [Full Text] [Related]
16. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
17. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.
Xiao X; Wang W; Zhang H; Gao P; Fan B; Huang C; Fu J; Chen G; Shi L; Zhu H; Li X; Li J; Fan H; Wu Z; Guo Z; Hu Y; Wu S; Yu X; Xu C; Wang Z
Tumour Biol; 2015 Apr; 36(4):2427-35. PubMed ID: 25431261
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
Hattinger CM; Patrizio MP; Luppi S; Serra M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629971
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
20. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Deeken JF; Figg WD; Bates SE; Sparreboom A
Anticancer Drugs; 2007 Feb; 18(2):111-26. PubMed ID: 17159598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
